Although mTOR inhibitors (everolimus, sirolimus) have been shown to improve clinical outcomes in preventing loss of lung function14,15 and have been approved to treat LAM, other pathways must be explored to improve patient treatment. This evidence concerns the gene MTOR and lymphangioleiomyomatosis.